Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
5
Stocks News & Analysis
stocks
AI stock rout: The US selloff in 4 charts
Worries about Western AI dominance permeated the markets, with Nvidia stock plunging 17% alongside other chipmakers, utilities, and more.
stocks
The ASX share to own forever
An updated outlook on Auckland Airport as we raise our fair value estimate.
stocks
Ask the analyst: Can this big Covid loser scale its former heights?
Corporate Travel Management saw its profits fall through the floor during the pandemic. Our analyst Brian Han answers a reader question on what might be next.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,644.50 | 15.90 | -0.18% |
| CAC 40 | 7,897.37 | 9.21 | -0.12% |
| DAX 40 | 21,430.58 | 148.40 | 0.70% |
| Dow JONES (US) | 44,850.35 | 136.77 | 0.31% |
| FTSE 100 | 8,533.87 | 30.16 | 0.35% |
| HKSE | 20,225.11 | 27.34 | 0.14% |
| NASDAQ | 19,733.59 | 391.75 | 2.03% |
| Nikkei 225 | 39,016.87 | 548.93 | -1.39% |
| NZX 50 Index | 12,972.33 | 15.18 | 0.12% |
| S&P 500 | 6,067.70 | 55.42 | 0.92% |
| S&P/ASX 200 | 8,399.10 | 9.80 | -0.12% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |